Physician profile
Cuong Le
NPI 1568997153
$10,066.28
in general payments reported to CMS, 2019-2025
24 companies · $3,396 in 2025
The $3,396 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.33 · 2021: $511 · 2022: $1,353 · 2023: $2,320 · 2024: $2,473 · 2025: $3,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,808 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,808.01 |
| Education | $380.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,825.97 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,632.15 | 2021-2025 | |
| Genzyme Corporation | $956.76 | 2021-2025 | |
| Galderma Laboratories, L.P. | $907.52 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $793.91 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $719.75 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $614.79 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $456.99 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $372.67 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $337.61 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $243.66 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $237.43 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $230.79 | 2022-2025 | |
| Organon LLC | $206.79 | 2025 | Vtama, Nexplanon |
| Sun Pharmaceutical Industries INC. | $136.47 | 2021-2023 | Absorica Ld, Winlevi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $120.61 | 2025 | |
| Almirall LLC | $62.53 | 2023-2025 | Klisyri |
| Journey Medical Corporation | $46.58 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $45.07 | 2021 | |
| Epi Health, LLC | $40.79 | 2022 | |
| Botanix Sb INC | $20.52 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $20.46 | 2024 | Sotyktu |
| Regeneron Pharmaceuticals, INC. | $18.26 | 2023 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.20 | 2025 | Siliq, Jublia, Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cuong Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.